TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Eledon Pharmaceuticals ( (ELDN) ) has provided an announcement.
On November 12, 2025, Eledon Pharmaceuticals entered into an underwriting agreement with Leerink Partners for a public offering of 15,152,485 shares of common stock and pre-funded warrants, aiming to raise approximately $46.5 million. The proceeds will support the clinical development of its product candidates and general corporate purposes, potentially increasing to $53.6 million if additional shares are purchased by underwriters.
The most recent analyst rating on (ELDN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Eledon Pharmaceuticals stock, see the ELDN Stock Forecast page.
Spark’s Take on ELDN Stock
According to Spark, TipRanks’ AI Analyst, ELDN is a Underperform.
Eldon Pharmaceuticals faces significant financial challenges with a lack of revenue and persistent losses, reflected in its low financial performance score. The stock’s technical indicators point towards a bearish trend, further compounded by a negative P/E ratio and no dividend yield. The company’s future hinges on successful product development or strategic financial interventions to improve its financial and market position.
To see Spark’s full report on ELDN stock, click here.
More about Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the clinical development of innovative therapies. The company is dedicated to advancing its pipeline programs to address unmet medical needs.
Average Trading Volume: 1,778,199
Technical Sentiment Signal: Sell
Current Market Cap: $113.2M
See more data about ELDN stock on TipRanks’ Stock Analysis page.